search
Back to results

Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.

Primary Purpose

Psoriasis Vulgaris

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Triamcinolone Acetonide Acetate and Urea Cream.
Qing-Re-Liang-Xue Decoction.
Sponsored by
The First Affiliated Hospital of Zhejiang Chinese Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psoriasis Vulgaris

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-65 years;
  • Had a diagnosis of psoriasis vulgaris for ≥6 months;
  • TCM syndrome evaluation belongs to blood-heat type patients: it is more common in the advanced stage of psoriasis. Symptoms: skin lesions develop faster, skin lesions are bright red, blood loss is obvious, scales are dry and thick, itching is severe; upset, and thirsty, dry stool; red-purple tongue, yellow fur, string or slippery or rapid pulse;
  • Patients without serious primary diseases, such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system or mental illnesses;
  • Those who are willing to cooperate and can persist in the treatment without interruption;
  • During the treatment period, those who have not taken or used other psoriasis drugs externally.

Exclusion Criteria:

  • Patients with serious primary diseases, such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system or mental illnesses;
  • History of immunosuppressant medication in the past three months;
  • Those who use other drugs during treatment or stop treatment on their own and have incomplete observation data;
  • Pregnancy or risk of pregnancy, and/or lactation;
  • Aged ≤18 or ≥65 years old;
  • Patients with other types of psoriasis, such as articular, pustular, and erythroderma.

Sites / Locations

  • First Affiliated Hospital of Zhejiang Chinese Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Qing-Re-Liang-Xue Decoction.

control group

Arm Description

One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.

Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.

Outcomes

Primary Outcome Measures

participants achieving either a major clinical response or partial clinical response defind by Psoriasis Area Severity Index (PASI) over the 10 weeks treatment period.
Psoriasis Area Severity Index (PASI) is usually used to measure the clinical activity diseases of psoriasis.

Secondary Outcome Measures

Changes in skin lesions are assessed by dermoscope.
Image data of skin lesions, capillaries in the nail bed, capillaries near the wing of the nose, etc will be analyzed by the Image-Pro Plus software(Version 6.0,Media Cybernetics) to figure out the inner diameter of the blood vessel wall thickness ratio, Wall cavity cross-sectional area ratio and density.
Evaluation of curative effect of Traditional Chinese medicine is assessed by patient reported outcome(PRO) and clinician reported outcomes(CRO).
Healed: TCM syndromes and skin lesions disappeared, only pigmentation spots or depigmentation spots remained, and no new skin rashes. The TCM syndrome score is reduced by more than 90%; markedly effective: TCM syndromes and skin lesions have basically disappeared or only a few intractable small pieces remain, and the skin lesions are still slightly infiltrated. TCM syndrome scores are reduced by 60-89%; effective: TCM syndromes are significantly reduced, and skin lesions have subsided by more than 30%. TCM syndrome scores are reduced by 30-56%; ineffective: after 3 courses of treatment, the skin lesions still have no progress or the skin lesions have subsided by less than 30%. The reduction of TCM syndrome points is less than 30%.
Compliance evaluation is assessed by Counting Days of Treatment.
Compliance=The number of days the subject has received treatment/The number of days the subject should receive treatment*100%

Full Information

First Posted
July 14, 2021
Last Updated
August 2, 2021
Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Collaborators
Pujiang Hospital of Traditional Chinese Medicine, Yongkang Hospital of Traditional Chinese Medicine, Ningbo Hospital of Traditional Chinese Medicine, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04994951
Brief Title
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
Official Title
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
September 2021 (Anticipated)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Collaborators
Pujiang Hospital of Traditional Chinese Medicine, Yongkang Hospital of Traditional Chinese Medicine, Ningbo Hospital of Traditional Chinese Medicine, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Psoriasis is a non-contagious erythematous scaly skin disease characterized by epidermal proliferation and inflammation. The etiology is related to heredity, infection, allergies, metabolic disorders and autoimmunity. The incidence of psoriasis in the survey was about 1.2‰ in 1984 in China, and 2.6% in the United States. In recent years, the incidence of psoriasis has been on the increase trend, mostly in the young to middle age adults, and it can last a lifetime. The characteristic of the disease is that it usually spreads all over the body, or gradually aggravates, or is fixed and difficult to subside,or the disease course is long, lingering and difficult to heal, and it brings great harm to the patient's body and mind. At present, there is no effective treatment for psoriasis. Although western medicine has good short-term curative effects, prolonged use is not advocated because of adverse side effects and poor long-term effects. Besides, it is easy to relapse and aggravate after stopping the medicine. Psoriasis belongs to the category of "baibi" in Chinese medicine. Doctors of the past dynasties mostly treated it from blood heat, blood stasis, and blood deficiency syndrome. Researcher Zhu Renkang believes that "blood with heat" is the main cause of psoriasis and famous TCM dermatologists such as Zhang Zhili, Gu Bohua, Xu Yihou and others all regard "blood-heat syndrome" as the basic pathogenesis of psoriasis. We used Qingre Liangxue Recipe Granules to observe the treatment of 31 patients with blood-heat type psoriasis vulgaris, and found that the PASI index of the patients after treatment was significantly lower than before treatment (P <0.01), and the serum VEGF level was significantly decreased (P < 0.01), the correlation analysis between the two showed a significant correlation. This study aims to further evaluate the efficacy and safety of Qing-Re-Liang-Xue Decoction in comparison with commonly used glucocorticoids and calcipotriol ointment in patients with blood-heat type psoriasis vulgaris.
Detailed Description
This is a multi-center, randomized, open-label, controlled pilot study of Traditional Chinese medicine (Qing-Re-Liang-Xue Decoction) as a complementary therapy to treat psoriasis vulgaris of blood-heat syndrome during a 10-week period. We estimate to enroll 200 subjects (treatment group(N=100); controlled group(N=100)).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psoriasis Vulgaris

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Qing-Re-Liang-Xue Decoction.
Arm Type
Experimental
Arm Description
One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
Arm Title
control group
Arm Type
Active Comparator
Arm Description
Topical steroids. Triamcinolone Acetonide Acetate and Urea Cream,10g/tube and Calcipotriol Ointment,10g/tube are used alternately. The period of treatment will be 10 weeks.
Intervention Type
Drug
Intervention Name(s)
Triamcinolone Acetonide Acetate and Urea Cream.
Intervention Description
10g/tube and CalcipotriolOintment,10g/tube are used alternately.
Intervention Type
Drug
Intervention Name(s)
Qing-Re-Liang-Xue Decoction.
Intervention Description
One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
Primary Outcome Measure Information:
Title
participants achieving either a major clinical response or partial clinical response defind by Psoriasis Area Severity Index (PASI) over the 10 weeks treatment period.
Description
Psoriasis Area Severity Index (PASI) is usually used to measure the clinical activity diseases of psoriasis.
Time Frame
10 weeks
Secondary Outcome Measure Information:
Title
Changes in skin lesions are assessed by dermoscope.
Description
Image data of skin lesions, capillaries in the nail bed, capillaries near the wing of the nose, etc will be analyzed by the Image-Pro Plus software(Version 6.0,Media Cybernetics) to figure out the inner diameter of the blood vessel wall thickness ratio, Wall cavity cross-sectional area ratio and density.
Time Frame
10 weeks.
Title
Evaluation of curative effect of Traditional Chinese medicine is assessed by patient reported outcome(PRO) and clinician reported outcomes(CRO).
Description
Healed: TCM syndromes and skin lesions disappeared, only pigmentation spots or depigmentation spots remained, and no new skin rashes. The TCM syndrome score is reduced by more than 90%; markedly effective: TCM syndromes and skin lesions have basically disappeared or only a few intractable small pieces remain, and the skin lesions are still slightly infiltrated. TCM syndrome scores are reduced by 60-89%; effective: TCM syndromes are significantly reduced, and skin lesions have subsided by more than 30%. TCM syndrome scores are reduced by 30-56%; ineffective: after 3 courses of treatment, the skin lesions still have no progress or the skin lesions have subsided by less than 30%. The reduction of TCM syndrome points is less than 30%.
Time Frame
10 weeks.
Title
Compliance evaluation is assessed by Counting Days of Treatment.
Description
Compliance=The number of days the subject has received treatment/The number of days the subject should receive treatment*100%
Time Frame
10 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-65 years; Had a diagnosis of psoriasis vulgaris for ≥6 months; TCM syndrome evaluation belongs to blood-heat type patients: it is more common in the advanced stage of psoriasis. Symptoms: skin lesions develop faster, skin lesions are bright red, blood loss is obvious, scales are dry and thick, itching is severe; upset, and thirsty, dry stool; red-purple tongue, yellow fur, string or slippery or rapid pulse; Patients without serious primary diseases, such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system or mental illnesses; Those who are willing to cooperate and can persist in the treatment without interruption; During the treatment period, those who have not taken or used other psoriasis drugs externally. Exclusion Criteria: Patients with serious primary diseases, such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system or mental illnesses; History of immunosuppressant medication in the past three months; Those who use other drugs during treatment or stop treatment on their own and have incomplete observation data; Pregnancy or risk of pregnancy, and/or lactation; Aged ≤18 or ≥65 years old; Patients with other types of psoriasis, such as articular, pustular, and erythroderma.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yi Cao, Master
Phone
0571-87077785
Email
caoyi1965@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaohong Yang
Phone
+86-15257128368
Email
yangxiaohonghz@163.com
Facility Information:
Facility Name
First Affiliated Hospital of Zhejiang Chinese Medical University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Cao, Doc.
Phone
0571-87077785
Email
caoyi1965@163.com
First Name & Middle Initial & Last Name & Degree
Xiaohong Yang, Doc.
Phone
+86-15257128368
Email
yangxiaohonghz@163.com
First Name & Middle Initial & Last Name & Degree
Yi Cao, Doc.
First Name & Middle Initial & Last Name & Degree
Xiaohong Yang, Doc.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.

We'll reach out to this number within 24 hrs